| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.2 | 4e-08 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.2 | 5e-08 |
| mRNA | 968 | CTRPv2 | pan-cancer | AAC | 0.38 | 5e-08 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.21 | 1e-07 |
| mRNA | (5Z)-7-Oxozeaenol | GDSC1000 | pan-cancer | AAC | -0.17 | 5e-07 |
| mRNA | BX-795 | GDSC1000 | pan-cancer | AAC | -0.19 | 8e-07 |
| mRNA | PI-103 | CTRPv2 | pan-cancer | AAC | 0.19 | 8e-07 |
| mRNA | OSI-906 | CTRPv2 | pan-cancer | AAC | 0.19 | 1e-06 |
| mRNA | dabrafenib | GDSC1000 | pan-cancer | AAC | -0.16 | 2e-06 |
| mRNA | Sunitinib | GDSC1000 | pan-cancer | AAC | -0.26 | 2e-06 |